Takura
Overview
Takura is a Swedish private investment company that acts as an early-stage developer of biopharma companies, focusing on bringing novel cell and gene therapies into clinical practice. It founds, funds, and builds companies, transforming scientific ideas into products. The company has a portfolio focused on advanced cell therapies, including mesenchymal stromal cells (MSC) and tumor-infiltrating lymphocytes (TIL). Takura was a key early investor in Cellcolabs, a company specializing in the industrial production of MSCs, which it later spun off to its shareholders in 2023 to focus on even earlier-stage biopharma development.
Portfolio Companies
2
Website
takura.seInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cellcolabs | Mar 2023 | VC Round | Co-investor |
| Valar Labs | Apr 2022 | Seed | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Takura based?
Takura is headquartered in Stockholm, Stockholm County, Sweden.
When was Takura founded?
Founding year information for Takura is not publicly available.
How many portfolio companies does Takura have?
Takura has 2 portfolio companies in Caplight's dataset.
What are some companies in Takura's portfolio?
Portfolio companies visible on Caplight include Cellcolabs, Valar Labs.
What was Takura's most recent investment shown here?
Takura's most recent investment in this portfolio sample was in Cellcolabs in 2023.
What sectors does Takura focus on?
Takura focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Takura focus on?
Takura typically invests at the Early stage.